A traditional Chinese medicine composition for treating ischemic stroke and its preparation method and application

Abstract

The present invention relates to a Chinese medicine composition for treating ischemic stroke, and a method and application thereof, and belongs to the technical field of traditional Chinese medicine. The Chinese medicine composition for treating ischemic stroke disclosed in the present invention comprises the following raw materials: ginseng, Panax notoginseng, processed Polygonum multiflorum, Chuanxiong, safflower, salvia miltiorrhiza, hawthorn, mistletoe, epimedium, kudzu root, buffalo horn, ginseng leaf, calamus, and borneol. In the present invention, Chuanxiong is fermented with a composite bacteria consisting of Lactobacillus plantarum, Bacillus subtilis, and Acoriformis scabra, so that more laccase and active substances are produced in the fermentation product. The fermentation product is then treated with the composite enzyme, and the Chuanxiong obtained by the treatment has better medicinal efficacy, thereby enhancing the therapeutic effect of the Chinese medicine composition for treating ischemic stroke, significantly alleviating neurological dysfunction caused by cerebral ischemia, and having a good protective effect on neurological damage caused by ischemic stroke.

Description

Technical Field

[0001] The present invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating ischemic stroke, and a preparation method and application thereof. Background Art

[0002] Chuanxiong is known as the "blood-qi medicine". It can regulate the body's blood circulation and improve the body's internal environment. Chuanxiong can improve the body's blood circulation by anti-coagulation, anti-thrombosis, increasing blood volume, vasodilation and lowering blood pressure, regulating the body's lipid metabolism and other pathways. Its active substances are mainly divided into: volatile oils, alkaloids, polysaccharides, organic acids, etc. The level of active content plays a very important role in the effect of efficacy. Different extraction methods will also affect the type and content of chemical components, and the pharmacological properties have differences. Currently, there are steam distillation, supercritical CO2 extraction, etc. These methods are not ideal for extracting the active ingredients of Chuanxiong. Therefore, the Chinese medicine composition for treating ischemic stroke provided by the present invention, as well as its preparation method and application, can effectively improve the extraction of active ingredients of Chuanxiong. Summary of the Invention

[0003] The present invention relates to a traditional Chinese medicine composition for treating ischemic stroke, and its preparation method and application, belonging to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition for treating ischemic stroke disclosed in the present invention comprises the following raw materials in parts by weight: 2-4 parts of ginseng, 5-7 parts of Panax notoginseng, 40-50 parts of processed Polygonum multiflorum, 10-20 parts of Chuanxiong, 10-15 parts of safflower, 30-50 parts of salvia miltiorrhiza, 25-30 parts of hawthorn, 25-30 parts of mistletoe, 26-30 parts of epimedium, 35-40 parts of kudzu root, 70-90 parts of buffalo horn, 15-25 parts of ginseng leaf, 10-15 parts of calamus, and 1-3 parts of borneol. In the present invention, Chuanxiong rhizome is fermented with a composite bacteria consisting of Lactobacillus plantarum, Bacillus subtilis and Porites crassifolia, so that more laccase and active substances are produced in the fermented product. The fermented product is then treated with the composite enzyme, and the Chuanxiong rhizome obtained by the treatment has better medicinal efficacy, thereby enhancing the blood circulation and analgesic effects of the traditional Chinese medicine composition, reducing the effect of neurological dysfunction caused by cerebral ischemia, and having a good protective effect on neurological damage caused by ischemic stroke.

[0004] The purpose of the present invention can be achieved through the following technical solutions:

[0005] A traditional Chinese medicine composition for treating ischemic stroke, comprising the following raw materials in parts by weight: 2-4 parts of ginseng, 5-7 parts of Panax notoginseng, 40-50 parts of processed Polygonum multiflorum, 10-20 parts of Chuanxiong, 10-15 parts of safflower, 30-50 parts of Salvia miltiorrhiza, 25-30 parts of hawthorn, 25-30 parts of mistletoe, 26-30 parts of epimedium, 35-40 parts of Pueraria root, 70-90 parts of buffalo horn, 15-25 parts of ginseng leaves, 10-15 parts of Acorus calamus, and 1-3 parts of borneol. A method for processing the Chuanxiong comprises the following steps:

[0006] A1 ： Grind the rhizome of Chuanxiong, sieve to form a powder, then add distilled water to mix, heat to sterilize, and cool to form a mixture;

[0007] A2: adding a composite bacteria to the mixture for mixed fermentation; adding a composite enzyme to the mixture after fermentation, mixing and then performing enzymatic hydrolysis; heating after enzymatic hydrolysis to inactivate the enzyme; filtering to obtain a filtrate a and a filter residue; adding distilled water to the filter residue, heating the mixture, and then filtering to obtain a filtrate b; combining the filtrate a and the filtrate b, and concentrating under reduced pressure to form an extract; and drying to complete the treatment steps;

[0008] Wherein, the composite bacteria consists of Aconitum carlesii, Bacillus subtilis and Lactobacillus plantarum;

[0009] The complex enzyme consists of cellulase and phospholipase.

[0010] Furthermore, the mesh size of the sieving in step A1 is 100-300 mesh, and the mass ratio of the powder to distilled water is 10-13:200-250.

[0011] Furthermore, the temperature and time for sterilization in step A1 are 120-150°C and 20-30 minutes respectively, and the cooling temperature is 25-35°C.

[0012] Furthermore, in step A2, the ratio of the mixture to the composite bacteria is 1-3L:0.05-0.08g, the mass ratio of Lactobacillus plantarum, Bacillus subtilis and Porites hirsutus is 1-2:1-1.5:1, and the temperature and time of the mixed fermentation are 30-38°C and 24-48h, respectively.

[0013] Furthermore, in step A2, the amount of the complex enzyme added is 3-5 wt% of the total mass of the system, the mass ratio of the cellulase to the phospholipase is 1:1, and the enzymatic hydrolysis conditions are: temperature 40-60° C., time 50-70 min.

[0014] Furthermore, in step A2, the temperature is raised to 120° C. to perform enzyme inactivation treatment.

[0015] Furthermore, in step A2, the volume ratio of the filter residue to distilled water is 1:1-2, the heating temperature is 80-100°C, the pressure of the reduced pressure concentration is -0.06 to -0.08 MPa, and the temperature is 60°C.

[0016] A Chinese medicine composition for treating ischemic stroke is used in the preparation of a medicine for treating ischemic stroke, wherein the medicine is a capsule. The invention has the following beneficial effects:

[0017] Ligusticum chuanxiong is fermented using a complex bacterial strain consisting of bursa pastoris, Lactobacillus plantarum, and Bacillus subtilis. Bursa pastoris produces laccase, while Lactobacillus plantarum and Bacillus subtilis synergistically promote the growth of bursa pastoris, significantly enhancing the activity of the laccase in the fermentation product. Laccase facilitates the degradation of compounds in Ligusticum chuanxiong, and the substances produced during the degradation process serve as a nutrient source for microbial growth. Furthermore, the fermentation product, combined with a complex enzyme consisting of cellulase and phospholipase, enhances the efficacy of the resulting Ligusticum chuanxiong, thereby enhancing the therapeutic effect of the traditional Chinese medicine composition for treating ischemic stroke. This composition can significantly reduce neurological dysfunction caused by cerebral ischemia and provide a protective effect against neurological damage caused by ischemic stroke. DETAILED DESCRIPTION

[0018] In order to further illustrate the technical means and effects adopted by the present invention to achieve the predetermined purpose of the invention, the specific implementation methods, structures, features and effects of the present invention are described in detail below in combination with the embodiments.

[0019] In the following examples, experimental methods without specific conditions were generally performed under conventional conditions or those recommended by the manufacturer. Materials and reagents used were commercially available unless otherwise specified.

[0020] The preservation number of the present invention is CCTCC No. M2021731, the preservation number of Bacillus subtilis is CGMCC No. 1.15792, and the preservation number of Lactobacillus plantarum is CGMCC No. 1.12974; and the effective viable count of Bacillus subtilis and Lactobacillus plantarum is 1*10 6 CFU / mL.

[0021] Cellulase was purchased from Hebei Tuohai Biotechnology Co., Ltd.;

[0022] Phospholipase was purchased from Chongqing Tianrun Biological Products Co., Ltd.;

[0023] SD rats: purchased from the Animal Experiment Center of Southern Medical University, production experimental animal license number: SCXK (Guangdong) 2021-0041; the experiment was conducted in the animal laboratory of the College of Veterinary Medicine of South China Agricultural University.

[0024] Example 1

[0025] A traditional Chinese medicine composition for treating ischemic stroke, comprising the following raw materials in parts by weight: 2 parts of ginseng, 5 parts of Panax notoginseng, 40 parts of processed Polygonum multiflorum, 10 parts of Chuanxiong, 10 parts of safflower, 30 parts of salvia miltiorrhiza, 25 parts of hawthorn, 25 parts of mistletoe, 26 parts of epimedium, 35 parts of kudzu root, 70 parts of buffalo horn, 15 parts of ginseng leaves, 10 parts of Acorus calamus, and 1 part of borneol. A method for processing the Chuanxiong comprises the following steps:

[0026] A1 ： Grind the rhizome of Chuanxiong, sieve to form a powder, then add distilled water to mix, heat to sterilize, and cool to form a mixture;

[0027] A2: adding a composite bacteria to the mixture for mixed fermentation; adding a composite enzyme to the mixture after fermentation, mixing and then performing enzymatic hydrolysis; heating after enzymatic hydrolysis to inactivate the enzyme; filtering to obtain a filtrate a and a filter residue; adding distilled water to the filter residue, heating the mixture, and then filtering to obtain a filtrate b; combining the filtrate a and the filtrate b, and concentrating under reduced pressure to form an extract; and drying to complete the treatment steps;

[0028] Wherein, the composite bacteria consists of Aconitum carlesii, Bacillus subtilis and Lactobacillus plantarum;

[0029] The deposit number of Psoralea corylifolia is CCTCC No.M2021731, the deposit number of Bacillus subtilis is CGMCC No.1.15792, and the deposit number of Lactobacillus plantarum is CGMCC No.1.12974;

[0030] The complex enzyme consists of cellulase and phospholipase.

[0031] The mesh number of the sieving in step A1 is 100 mesh, and the mass ratio of the powder to distilled water is 10:200.

[0032] The temperature and time for heating and sterilizing in step A1 are 120° C. and 20 min respectively, and the cooling temperature is 25° C.

[0033] The ratio of the mixture to the composite bacteria in step A2 is 1 L:0.05 g, the mass ratio of Lactobacillus plantarum, Bacillus subtilis and Porites hirsutus is 1:1:1, and the temperature and time of the mixed fermentation are 30° C. and 24 h, respectively.

[0034] The amount of the complex enzyme added in step A2 is 3 wt % of the total mass of the system, the mass ratio of the cellulase to the phospholipase is 1:1, the enzymolysis temperature is 40° C., and the enzymolysis time is 50 min.

[0035] In step A2, the temperature is raised to 120°C for enzyme inactivation. In step A2, the volume ratio of the filter residue to distilled water is 1:1, the heating temperature is 80°C, and the pressure of the reduced pressure concentration is -0.06 MPa and the temperature is 60°C.

[0036] The drying in step A2 is freeze-drying.

[0037] Example 2

[0038] A traditional Chinese medicine composition for treating ischemic stroke, comprising the following raw materials in parts by weight: 3 parts of ginseng, 6 parts of Panax notoginseng, 45 parts of processed Polygonum multiflorum, 15 parts of Chuanxiong, 13 parts of safflower, 40 parts of salvia miltiorrhiza, 28 parts of hawthorn, 28 parts of mistletoe, 28 parts of epimedium, 38 parts of kudzu root, 80 parts of buffalo horn, 20 parts of ginseng leaves, 13 parts of Acorus calamus, and 2 parts of borneol. A method for processing the Chuanxiong comprises the following steps:

[0039] A1 ： Grind the rhizome of Chuanxiong, sieve to form a powder, then add distilled water to mix, heat to sterilize, and cool to form a mixture;

[0040] A2: adding a composite bacteria to the mixture for mixed fermentation; adding a composite enzyme to the mixture after fermentation, mixing and then performing enzymatic hydrolysis; heating after enzymatic hydrolysis to inactivate the enzyme; filtering to obtain a filtrate a and a filter residue; adding distilled water to the filter residue, heating the mixture, and then filtering to obtain a filtrate b; combining the filtrate a and the filtrate b, and concentrating under reduced pressure to form an extract; and drying to complete the treatment steps;

[0041] Wherein, the composite bacteria consists of Aconitum carlesii, Bacillus subtilis and Lactobacillus plantarum;

[0042] The deposit number of Psoralea corylifolia is CCTCC No.M2021731, the deposit number of Bacillus subtilis is CGMCC No.1.15792, and the deposit number of Lactobacillus plantarum is CGMCC No.1.12974;

[0043] The complex enzyme consists of cellulase and phospholipase.

[0044] The mesh size of the sieve in step A1 is 200 mesh, and the mass ratio of the powder to distilled water is 12:225.

[0045] The temperature and time for heating and sterilizing in step A1 are 135° C. and 25 min respectively, and the cooling temperature is 30° C.

[0046] The ratio of the mixture to the composite bacteria in step A2 is 2L:0.06g, the mass ratio of Lactobacillus plantarum, Bacillus subtilis and Porites hirsutus is 1.5:1.3:1, and the temperature and time of the mixed fermentation are 34°C and 34h, respectively.

[0047] The amount of the complex enzyme added in step A2 is 4 wt % of the total mass of the system, the mass ratio of the cellulase to the phospholipase is 1:1, and the enzymatic hydrolysis conditions are: temperature 50° C., time 60 min.

[0048] In step A2, the temperature is raised to 120° C. to perform enzyme inactivation treatment.

[0049] In step A2, the volume ratio of the filter residue to distilled water is 1:1.5, the heating temperature is 90° C., the pressure of the reduced pressure concentration is -0.07 MPa, and the temperature is 60° C.

[0050] The drying in step A2 is freeze-drying.

[0051] Example 3

[0052] A traditional Chinese medicine composition for treating ischemic stroke, comprising the following raw materials in parts by weight: 4 parts of ginseng, 7 parts of Panax notoginseng, 50 parts of processed Polygonum multiflorum, 20 parts of Chuanxiong, 15 parts of safflower, 50 parts of salvia miltiorrhiza, 30 parts of hawthorn, 30 parts of mistletoe, 30 parts of epimedium, 40 parts of kudzu root, 90 parts of buffalo horn, 25 parts of ginseng leaves, 15 parts of Acorus calamus, and 3 parts of borneol. A method for processing the Chuanxiong comprises the following steps:

[0053] A1: Grind and sieve Chuanxiong to form a powder, then add distilled water and mix, heat and sterilize, and cool to form a mixture;

[0054] A2: adding a composite bacteria to the mixture for mixed fermentation; adding a composite enzyme to the mixture after fermentation, mixing and then performing enzymatic hydrolysis; heating after enzymatic hydrolysis to inactivate the enzyme; filtering to obtain a filtrate a and a filter residue; adding distilled water to the filter residue, heating the mixture, and then filtering to obtain a filtrate b; combining the filtrate a and the filtrate b, and concentrating under reduced pressure to form an extract; and drying to complete the treatment steps;

[0055] Wherein, the composite bacteria consists of Aconitum carlesii, Bacillus subtilis and Lactobacillus plantarum;

[0056] The deposit number of Psoralea corylifolia is CCTCC No.M2021731, the deposit number of Bacillus subtilis is CGMCC No.1.15792, and the deposit number of Lactobacillus plantarum is CGMCC No.1.12974;

[0057] The complex enzyme consists of cellulase and phospholipase.

[0058] The mesh size of the sieve in step A1 is 300 mesh, and the mass ratio of the powder to distilled water is 13:250.

[0059] The temperature and time for heating and sterilizing in step A1 are 150° C. and 30 min respectively, and the cooling temperature is 35° C.

[0060] The ratio of the mixture to the composite bacteria in step A2 is 3L:0.08g, the mass ratio of Lactobacillus plantarum, Bacillus subtilis and Porites hirsutus is 2:1.5:1, and the temperature and time of the mixed fermentation are 38°C and 48h, respectively.

[0061] The amount of the complex enzyme added in step A2 is 5 wt % of the total mass of the system, the mass ratio of the cellulase to the phospholipase is 1:1, and the enzymatic hydrolysis conditions are: temperature 60° C., time 70 min.

[0062] In step A2, the temperature is raised to 120° C. to perform enzyme inactivation treatment.

[0063] In step A2, the volume ratio of the filter residue to distilled water is 1:2, the heating temperature is 100° C., the pressure of the reduced pressure concentration is -0.08 MPa, and the temperature is 60° C.

[0064] The drying in step A2 is freeze-drying.

[0065] Comparative Example 1

[0066] Compared with Example 2, the only difference is that the composite bacteria in Comparative Example 1 does not contain Lactobacillus plantarum, and its reduced mass is proportionally distributed to the masses of Bacillus subtilis and Pseudomonas aeruginosa. Other conditions are the same as those in Example 2.

[0067] Comparative Example 2

[0068] Compared with Example 2, the only difference is that the composite bacteria in Comparative Example 2 does not contain Bacillus subtilis, and the reduced mass thereof is proportionally distributed to the masses of Lactobacillus plantarum and Pseudomonas aeruginosa. Other conditions are the same as those in Example 2.

[0069] Comparative Example 3

[0070] Compared with Example 2, the only difference is that the mass ratio of Acanthopanax spp., Lactobacillus plantarum and Bacillus subtilis is 3:2:1, and other conditions are the same as those in Example 2.

[0071] Comparative Example 4

[0072] Compared with Example 2, the only difference is that the mass ratio of Acanthopanax spp., Lactobacillus plantarum and Bacillus subtilis is 0.5:0.5:1, and other conditions are the same as those in Example 2.

[0073] Comparative Example 5

[0074] Compared with Example 2, the only difference is that the Bacillus subtilis with a deposit number of CGMCC No. 1.12939 is used instead of the Bacillus subtilis with a deposit number of CGMCC No. 1.15792, and other conditions are the same as those in Example 2.

[0075] Comparative Example 6

[0076] Based on Example 2, the only difference is that Lactobacillus plantarum with a preservation number of CGMCC No. 1.12935 is used to replace Lactobacillus plantarum with a preservation number of CGMCC No. 1.12974, and other conditions are the same as those in Example 2.

[0077] Performance Testing

[0078] 1) Determination of laccase: ABTS method was used for determination

[0079] The fermented liquid in step A2 of Example 1-3 and Comparative Example 1-6 was used as a sample. 5 times the volume of distilled water was added to the sample and the mixture was heated at 4°C and 3000 r·min. -1 Centrifuge for 20 minutes and take the supernatant. Take 2.9 ml of 0.5 mmol / L ABTS solution into a 1 cm cuvette and quickly transfer it to a 30°C water bath to preheat for 5 minutes. Pipette 0.1 ml of the supernatant diluted 6000 times to start the reaction. Measure the absorbance (OD value) change within 4 minutes at a wavelength of 420 nm and record the △OD value. The amount of enzyme required to oxidize 1 μmol ABTS per minute is one enzyme activity unit. Calculate the laccase (Lac) activity according to the following formula: Lac = (△OD × n × 1 ml × 10 6 μmol / mol)÷(0.1ml×4min×ε), where the extinction coefficient ε=3.6×10 4 M -1 cm -1 , n is the enzyme solution dilution multiple, and the test results are shown in Table 1.

[0080] Table 1 Test results

[0081] Sample Laccase (Lac) activity / U Example 1 7500 Example 2 7800 Example 3 7600 Comparative Example 1 4600 Comparative Example 2 4300 Comparative Example 3 5600 Comparative Example 4 5400 Comparative Example 5 6800 Comparative Example 6 6700

[0082] Analysis of the data in Table 1 reveals that the laccase activity of Examples 1-3 is much greater than that of Comparative Examples 1-6. Comparative Examples 1-2, which lack either Lactobacillus plantarum or Bacillus subtilis, show significantly lower laccase activity in their fermentation broths compared to Examples 1-3. Comparative Examples 3-4, in which the ratios of Psoralea corylifolia, Lactobacillus plantarum, and Bacillus subtilis were adjusted, also show reduced laccase activity compared to the Examples. The experimental data from Comparative Examples 5-6 demonstrate that replacing different strains of Bacillus subtilis and Lactobacillus plantarum also affects laccase activity in the fermentation broth.

[0083] 2) Animal experiment: 110 healthy male SPF-grade SD rats, weighing 250±50g, were selected. The breeding conditions were: room temperature between 22 and 24°C, humidity between 40 and 70%, alternating light and dark lighting time of 12h, and free drinking water and food intake. Referring to the animal experiment in patent CN111700947A, the specific method is: SD rats were randomly divided into a sham operation group (normal group), a cerebral ischemia reperfusion group (model group) and 9 drug groups, with 10 rats in each group. Before use, the Chinese medicine composition was obtained according to the corresponding method of the embodiment and the comparative example, and then the suspension was made with normal saline. The drug group was gavaged with the corresponding drug suspension, and the sham operation group and the model group were gavaged with equal amounts of normal saline, and the drug was gavaged once in the morning and evening every day. The neurobehavioral score of each group of rats was measured 24h after gavage, and the cerebral infarction volume ratio was measured 72h after gavage. The specific method is as follows:

[0084] Cerebral ischemia-reperfusion model: A middle cerebral artery occlusion (MCAO) model was established using a modified suture embolization method described by Longa et al. Rats were anesthetized with sodium pentobarbital, fixed in the supine position, and disinfected with alcohol. A 1-cm midline cervical incision was performed, and blunt dissection was performed to expose the right common carotid artery (CCA), external carotid artery (ECA), and internal carotid artery (ICA). The ECA was ligated, and the CCA was temporarily occluded with a fine suture. The distal end of the ICA was temporarily clamped with a micro-arteriolar clamp. A V-shaped cut was made in the ECA near the bifurcation. A 40-mm-long fishing line with a 0.4-mm diameter tip was inserted through the cut, from the ECA to the ICA, and gently advanced along the course of the ICA, avoiding the pterygopalatine artery. The line was advanced approximately 19 mm and stopped when resistance was encountered. The line was then secured to the ECA. After 90 minutes of ischemia, the suture was removed to allow reperfusion, and the ECA was ligated near the bifurcation. The incision was sutured and disinfected with alcohol to prevent infection. No fishing line was inserted in the sham operation group. Other experimental steps were the same as above.

[0085] Neurological function scoring: Rats were graded according to the 0-3 scale of Bederson et al., and neurological deficits were observed and recorded 24 hours after modeling: no neurological deficits were graded as 0; flexion of the limb contralateral to the lesion when the tail was lifted was graded as 1; in addition to grade 1 signs, there was a decrease in resistance to lateral push toward the side contralateral to the lesion was graded as 2; in addition to grade 1 and grade 2 signs, there was a sign of rotation toward the paralyzed side during activity was graded as 3. Rats that died during surgery or had skull base hemorrhage after autopsy were excluded.

[0086] Cerebral infarction volume ratio: After oral administration of the drug, rats were decapitated and their brains were quickly frozen at -20°C for 10 minutes. Once the brains reached a certain hardness, they were removed and six coronal sections, each 2.5 mm thick, were cut along a ruler from the frontal pole of the forebrain using a sharp blade. The brain slices were placed in 2% TTC staining solution and incubated at 37°C for 30 minutes. The slices were then fixed in freshly prepared 10% formaldehyde solution. The brain slices were arranged in the order in which they were sliced, photographed with a digital camera, and entered into a computer. Image analysis was used to calculate the ischemic area of ​​each slice and the total area, and then the infarct area ratio was calculated.

[0087] The experimental data were analyzed by variance using SPSS statistical software, and P < 0.05 indicated that the difference was statistically significant.

[0088] The experimental results are shown in Table 2.

[0089] Table 2 Effects of neurobehavioral scores and cerebral infarction volume ratio in rats

[0090] Group Rating impact / 24h Cerebral infarction volume ratio Model Group 2.62±0.25 0.284±0.038 Sham operation group 0.22±0.28 0 Example 1 <![CDATA[1.56±0.55 ＊ ]]> <![CDATA[0.048±0.035 ＊＊ ]]> Example 2 <![CDATA[1.42±0.63 ＊ ]]> <![CDATA[0.046±0.036 ＊＊ ]]> Example 3 <![CDATA[1.58±0.54 ＊ ]]> <![CDATA[0.050±0.041 ＊＊ ]]> Comparative Example 1 2.35±0.84 0.234±0.054 Comparative Example 2 2.28±0.71 0.236±0.062 Comparative Example 3 2.15±0.51 0.219±0.075 Comparative Example 4 2.18±0.69 0.217±0.052 Comparative Example 5 1.98±0.75 <![CDATA[0.164±0.032 ＊ ]]> Comparative Example 6 1.89±0.87 <![CDATA[0.166±0.042 ＊ ]]>

[0091] Note: “*” represents P < 0.05, “**” represents P < 0.01, compared with the model group.

[0092] As can be drawn from Table 2, compared with the model group, the neurological function scores of Examples 1-3 have significant differences, indicating that the Chinese medicine composition of the present invention can significantly alleviate the symptoms of neurological impairment in rats (P < 0.05), and compared with the model group, the cerebral infarction volume ratio also has a very significant difference (P < 0.01). In addition, by comparing the experimental data of the embodiments with those of other comparative examples, it is shown that the present invention adopts a composite bacteria formed by a specific ratio of Acanthopanax bursa-pastoris, Lactobacillus plantarum, and Bacillus subtilis to ferment Chuanxiong, and the enzyme treatment is adopted after the three synergistic fermentation, and the Chuanxiong obtained by the treatment is better, thereby enhancing the therapeutic effect of the Chinese medicine composition for the treatment of ischemic stroke, can alleviate the neurological dysfunction caused by transient cerebral ischemia in rats, can significantly reduce the cerebral infarction volume in rats, and has a good protective effect on ischemic stroke nerve damage.

[0093] The above description is merely a preferred embodiment of the present invention and does not constitute any form of limitation to the present invention. Although the present invention has been disclosed as above in terms of a preferred embodiment, it is not intended to limit the present invention. Any person skilled in the art can, without departing from the scope of the technical solution of the present invention, make some changes or modifications to equivalent embodiments using the technical contents disclosed above. However, any brief modifications, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention are still within the scope of the technical solution of the present invention.

Claims

1. A Chinese medicine composition for treating ischemic stroke, characterized in that: The Chinese medicine composition for treating ischemic stroke is composed of the following raw materials in parts by weight: 2-4 parts of ginseng, 5-7 parts of Panax notoginseng, 40-50 parts of processed Polygonum multiflorum, 10-20 parts of Chuanxiong, 10-15 parts of safflower, 30-50 parts of Salvia miltiorrhiza, 25-30 parts of hawthorn, 25-30 parts of mistletoe, 26-30 parts of epimedium, 35-40 parts of Pueraria root, 70-90 parts of buffalo horn, 15-25 parts of ginseng leaves, 10-15 parts of Acorus calamus, and 1-3 parts of borneol. The method for processing Chuanxiong comprises the following steps: A1: Grind and sieve Chuanxiong to form a powder, then add distilled water and mix, heat and sterilize, and cool to form a mixture; A2: adding a composite bacteria to the mixture for mixed fermentation; adding a composite enzyme to the mixture after fermentation, mixing and then performing enzymatic hydrolysis; heating after enzymatic hydrolysis to inactivate the enzyme; filtering to obtain a filtrate a and a filter residue; adding distilled water to the filter residue, heating the mixture, and then filtering to obtain a filtrate b; combining the filtrate a and the filtrate b, and concentrating under reduced pressure to form an extract; and drying to complete the treatment steps; Wherein, the composite bacteria consists of Aconitum carlesii, Bacillus subtilis and Lactobacillus plantarum; The complex enzyme consists of cellulase and phospholipase; In step A2, the ratio of the mixture to the composite bacteria is 1-3L:0.05-0.08g, the mass ratio of Lactobacillus plantarum, Bacillus subtilis and Porites hirsutus is 1-2:1-1.5:1, and the temperature and time of the mixed fermentation are 30-38°C and 24-48h, respectively; In step A2, the amount of the complex enzyme added is 3-5 wt% of the total mass of the system, the mass ratio of the cellulase and phospholipase is 1:1, and the enzymatic hydrolysis conditions are: temperature 40-60°C, time 50-70 min; The preservation number of the Acanthopanax spp. is CCTCC No. M2021731, the preservation number of Bacillus subtilis is CGMCC No. 1.15792, and the preservation number of Lactobacillus plantarum is CGMCC No. 1.12974.

2. A Chinese medicine composition for treating ischemic stroke according to claim 1, characterized in that: The mesh size of the sieving in step A1 is 100-300 mesh, and the mass ratio of the powder to distilled water is 10-13:200-250.

3. A Chinese medicine composition for treating ischemic stroke according to claim 1, characterized in that: The temperature and time for sterilization in step A1 are 120-150° C. and 20-30 min respectively, and the cooling temperature is 25-35° C.

4. A Chinese medicine composition for treating ischemic stroke according to claim 1, characterized in that: In step A2, the temperature is raised to 120° C. to perform enzyme inactivation treatment.

5. A Chinese medicine composition for treating ischemic stroke according to claim 1, characterized in that: In step A2, the volume ratio of the filter residue to distilled water is 1:1-2, the heating temperature is 80-100° C.; the pressure of the reduced pressure concentration is -0.06 to -0.08 MPa, and the temperature is 60° C.

6. Use of the traditional Chinese medicine composition for treating ischemic stroke according to any one of claims 1 to 5 in preparing a medicament for treating ischemic stroke, characterized in that: The medicine is a capsule.